7-Hydroxymethyl-10,11-MDCPT

Cat. No.: HY-156756 Purity: 96.38%: FAQs
Data Sheet SDS COA Handling Instructions Technical Support

7-Hydroxymethyl-10,11-MDCPT is a payload that can be used for ADC synthesis.

For research use only. We do not sell to patients.

7-Hydroxymethyl-10,11-MDCPT Chemical Structure

Size	Stock	Quantity
1 mg	In-stock	Estimated Time of Arrival: December 31
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	Get quote
50 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of 7-Hydroxymethyl-10,11-MDCPT:

7-Hydroxymethyl-10,11-MDCPT-d₅ Get quote

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All ADC Cytotoxin Isoform Specific Products:

View All Isoforms

Auristatin Calicheamicins Camptothecins Daunorubicins/Doxorubicins Duocarmycins Maytansinoids Pyrrolobenzodiazepines Traditional Cytotoxic Agents

Biological Activity
Purity & Documentation
References
Customer Review

Description	7-Hydroxymethyl-10,11-MDCPT is a payload that can be used for ADC synthesis^[1].
Molecular Weight	422.39
Formula	C₂₂H₁₈N₂O₇
CAS No.	428816-69-7
Appearance	Solid
Color	Off-white to light yellow
SMILES	OCC1=C2C(C(N3C2)=CC([C@](O)(C(OC4)=O)CC)=C4C3=O)=NC5=CC(OCO6)=C6C=C51
Shipping	Room temperature in continental US; may vary elsewhere.
Storage	-20°C, sealed storage, away from moisture and light *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Purity & Documentation	Purity: 96.38% Select Batch: Data Sheet (273 KB) SDS (252 KB) COA (257 KB) HNMR (466 KB) RP-HPLC (269 KB) LCMS (93 KB) Handling Instructions (2659 KB)
References	[1]. Cai JQ, Human anti-human HER3 antibodies and ADCs or drug conjugates for therapy, prevention and diagnosis of cancer or infection. 2023. WO2023143263 [2]. Wadkins RM, et al. Hydrophilic camptothecin analogs that form extremely stable cleavable complexes with DNA and topoisomerase I. Cancer Res. 2004 Sep 15;64(18):6679-83. [Content Brief]